BNTC Benitec Biopharma Inc

Price (delayed)

$8.15

Market cap

$294.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.02

Enterprise value

$118.53M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 20
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” ...

Highlights
The debt has contracted by 21% YoY and by 16% from the previous quarter
The equity has soared by 81% YoY but it has contracted by 4.2% from the previous quarter
The company's EPS rose by 4.7% YoY but it fell by 4.1% QoQ
The company's quick ratio has shrunk by 58% YoY and by 42% QoQ
BNTC's net income is down by 18% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of BNTC

BNTC stock price

How has the Benitec Biopharma stock price performed over time
Intraday
-4.57%
1 week
-12.18%
1 month
0.49%
1 year
-39.76%
YTD
-39.5%
QTD
-18.5%

Financial performance

How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.87M
Net income
-$49.51M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 22% year-on-year and by 9% since the previous quarter
BNTC's net income is down by 18% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does BNTC's price correlate with its fundamentals

Growth

What is Benitec Biopharma's growth rate over time

Valuation

What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
1.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 4.7% YoY but it fell by 4.1% QoQ
The equity has soared by 81% YoY but it has contracted by 4.2% from the previous quarter
BNTC's P/B is 50% below its 5-year quarterly average of 3.5 and 23% below its last 4 quarters average of 2.3

Efficiency

How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has increased by 40% YoY and by 2.8% QoQ
Benitec Biopharma's ROA has increased by 39% YoY and by 3.6% from the previous quarter

Dividends

What is BNTC's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Benitec Biopharma financials performed over time
The company's total assets has surged by 87% YoY
Benitec Biopharma's total liabilities has soared by 68% from the previous quarter
The debt is 100% less than the equity
The debt to equity has plunged by 100% YoY
The equity has soared by 81% YoY but it has contracted by 4.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.